Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Nicia I. Profili, Roberto Castelli, Antonio Gidaro, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5161-5161
Open Access | Times Cited: 9

Showing 9 citing articles:

Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials
Francisco Cézar Aquino de Moraes, Artur de Oliveira Macena Lôbo, Vitor Kendi Tsuchiya Sano, et al.
Clinical Oncology (2024) Vol. 36, Iss. 10, pp. e408-e419
Closed Access | Times Cited: 5
Diabetes und onkologische Immuntherapien: Schwerer Autoimmundiabetes durch Immuntherapien möglich
Tim Brandenburg, Jasmin M. Klose, Joachim Feldkamp, et al.
Deutsches Ärzteblatt (2025)
Closed Access
Hypothyroidism following immunotherapy predicts more postoperative complication in oral squamous cell carcinoma
Wenwen Zhang, Ping Lu, Xing Li, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature
Peng Ning, Shilan Liu, Hongyi Cao
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibition for Malignancies
Shlomit Shalitin
Hormone Research in Paediatrics (2024), pp. 1-12
Closed Access | Times Cited: 3
Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria
Anna Angelousi, Dimitrios C. Ziogas, Vasiliki Siampanopoulou, et al.
Diseases (2024) Vol. 12, Iss. 2, pp. 40-40
Open Access | Times Cited: 2
Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis
Ping Yang, Guoshuang Shen, Hengheng Zhang, et al.
International Immunopharmacology (2024) Vol. 133, pp. 111961-111961
Closed Access | Times Cited: 2
Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, MEN1 Gene-Related Tumors, and Insulin Resistance
Mara Carşote, Claudiu Nistor, Ana-Maria Gheorghe, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6349-6349
Open Access | Times Cited: 1
Analysis of immune‐related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors
Chengu Niu, Kaiwen Zhu, Jing Zhang, et al.
International Journal of Cancer (2023) Vol. 154, Iss. 7, pp. 1261-1271
Open Access | Times Cited: 2
Immune checkpoint inhibitor therapy for breast cancer
Mingzhe Li
MedScien (2024) Vol. 1, Iss. 7
Open Access
Page 1

Scroll to top